Efficacy of Epalrestat and Benfotiamine in Reducing Nerve Damage in Patients with Diabetes Mellitus (Type 2 Diabetes)
Not Applicable
- Conditions
- Health Condition 1: null- Diabetic Neuropathy
- Registration Number
- CTRI/2017/08/009577
- Lead Sponsor
- JIPMER Intramural fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with type 2 diabetes mellitus presenting to the
diabetology clinic of Medicine outpatient department (OPD) diagnosed to have diabetic neuropathy with symptoms of paresthesia,
dysesthesia, numbness, hypoesthesia (but not anesthesia).
Exclusion Criteria
1. Patients with peripheral vascular diseases
2. Patients taking Vitamin B12, Vitamin B6, alpha lipoic acid, gabapentin,
pregabalin, duloxetine and amitryptiline.
3. Patients with renal and hepatic dysfunction and congestive cardiac failure
4. Patients without reasonably good levels of HbA1c( >8.5)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method